<unk> , sold under the brand name Cotellic, is an anti-cancer medication used in combination with vemurafenib (Zelboraf) alone or with both vemurafenib and atezolizumab (Tecentriq) to treat melanoma.<unk>  is a MEK inhibitor. Cotellic, Zelboraf, and Tecentriq are all marketed by Genentech, a subsidiary of Roche. The most common side effects include diarrhea, rash, nausea (feeling sick), vomiting, pyrexia (fever), photosensitivity (light sensitivity) reaction, abnormal results for certain liver function tests (increased levels of alanine aminotransferase, aspartate aminotransferase) and abnormal results for an enzyme related to muscle breakdown (creatine phosphokinase).<unk>  was approved for medical use in the United States in November 2015.
Cobimetinib
Binimetinib
Selumetinib
Pralsetinib
Lestaurtinib
Nilotinib
Luspatercept
Gefitinib